Sorivudine

This classification denotes a dihydropyrimidine dehydrogenase inhibitor with the molecular formula C11H13BrN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C7VOZ162LV, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)- but generally known as sorivudine, which bears US NIH Compound Identifier 5282192. European Medicines Agency schedules Sorivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10605MIG. The term SORIVUDINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 5, No. 3 1991, List 31). SORIVUDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule sorivudine under HS 29349990 and SITC 51579. As of Q4 2014, SORIVUDINE remains the US FDA Preferred Term for this commodity. Sorivudine bears US NLM identifiers UMLS ID C0207628 and NCI Concept Code C1460. SMILES: C1=C(C(=O)NC(=O)N1C2C(C(C(O2)CO)O)O)C=CBR.